Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus docetaxel biomarker phase II trial in previously treated NSCLC
2014-003891-22Phase 2Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Aug 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Medical University of Innsbruck. Primary endpoint: Progression-free survival in conjunction with biomarker analysis. Started Aug 2015; status: terminated.
02
Drugs
nintedanibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-003891-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003891-22.